| Literature DB >> 36080487 |
Yuanhang Ren1,2,3, Xuan He3, Xiyue Yan3, Yanting Yang3, Qiang Li1,2,3, Tian Yao1,3, Lidan Lu3, Lianxin Peng1,2,3, Liang Zou1,2,3.
Abstract
Chlorfenapyr (CHL) is a type of insecticide with a wide range of insecticidal activities and unique targets. The extensive use of pesticides has caused an increase in potential risks to the environment and human health. However, the potential toxicity of CHL and its mechanisms of action on humans remain unclear. Therefore, human liver cells (HepG2) were used to investigate the cytotoxic effect and mechanism of toxicity of CHL at the cellular level. The results showed that CHL induced cellular toxicity in HepG2 cells and induced mitochondrial damage associated with reactive oxygen species (ROS) accumulation and mitochondrial calcium overload, ultimately leading to apoptosis and autophagy in HepG2 cells. Typical apoptotic changes occurred, including a decline in the mitochondrial membrane potential, the promotion of Bax/Bcl-2 expression causing the release of cyt-c into the cytosol, the activation of cas-9/-3, and the cleavage of PARP. The autophagic effects included the formation of autophagic vacuoles, accumulation of Beclin-1, transformation of LC3-II, and downregulation of p62. Additionally, DNA damage and cell cycle arrest were detected in CHL-treated cells. These results show that CHL induced cytotoxicity associated with mitochondria-mediated programmed cell death (PCD) and DNA damage in HepG2 cells.Entities:
Keywords: Chlorfenapyr; DNA damage; HepG2 cells; apoptosis; autophagy; cell cycle
Mesh:
Substances:
Year: 2022 PMID: 36080487 PMCID: PMC9457613 DOI: 10.3390/molecules27175722
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Cytoactivity of chlorfenapyr (CHL) against HepG2 cells under various concentrations at various lengths of time. Distinct letters above the columns indicate significant differences at p ≤ 0.05.
Figure 2Analysis of ROS production and antioxidant enzyme activity in HepG2 cells after treatment with CHL. (A): Analysis of DCF staining by epifluorescence (200×). (B): Analysis of DCF staining by flow cytometry. (C): Quantification of ROS levels. (D): Activity of SOD and CAT enzymes. ** p ≤ 0.01 vs. the negative control.
Figure 3Analysis of MMP loss in HepG2 cells after treatment with CHL. (A): Analysis of JC-1 staining by flow cytometry. (B): Analysis of Rh123 staining by epifluorescence (200×). (C): Quantification levels of MMP loss. ** p ≤ 0.01 vs. the negative control.
Figure 4Analysis of cytosolic and mitochondrial Ca2+ levels in HepG2 cells after treatment with CHL. (A,C): Analysis of Fluo-3 and Rhod-2 staining by flow cytometry. (B): Quantification levels of Fluo-3 fluorescence. (D): Quantification levels of Rhod-2 fluorescence. ** p ≤ 0.01 vs. the negative control.
Figure 5Analysis of apoptotic effects of HepG2 cells after treatment with CHL. (A): Analysis of Annexin V/PI staining by flow cytometry. (B): Quantification of apoptotic cells. (C): Expression of apoptotic proteins by Western blot. (D): Quantification levels of apoptotic proteins. (E): Evaluation of caspase-3/9 activity by spectrophotometric analysis. ** p ≤ 0.01 and * p ≤ 0.05 vs. the negative control.
Figure 6Analysis of autophagic effects of HepG2 cells after treatment with CHL. Observation of autophagy characteristics in HepG2 cells via TEM. (A): Control cells with normal mitochondria in well shape. (B,C): 30 μM (B) or 60 μM (C) CHL-treated cells with autophagic vacuoles (red arrows). (D): Analysis of MDC staining by epifluorescence (200×). (E): Expression of autophagy-associated proteins by Western blot. (F): Quantification levels of autophagy-associated proteins. ** p ≤ 0.01 and * p ≤ 0.05 vs. the negative control.
Figure 7Analysis of the quantity of mitochondria in HepG2 cells after treatment with CHL. The change trends of Mito-tracker and Lyso-tracker’s fluorescence intensity were detected by epifluorescence (200×).
Figure 8Analysis of the DNA damage and cell cycle in HepG2 cells after treatment with CHL. (A): Expression of PARP, γH2AX, and OGG1 by Western blot. (B): Quantification levels of γH2AX and OGG1. (C): Analysis of cell cycle by flow cytometry. (D), Proportion of cell cycle phases (G1, S, and G2). ** p ≤ 0.01 and * p ≤ 0.05 vs. the negative control.